OvaScience, Inc. (OVAS) Milestone Rewards Option Bulls

OvaScience Inc's (OVAS) Augment fertility treatment produced its first birth

May 7, 2015 at 2:55 PM
facebook twitter linkedin


OvaScience Inc (NASDAQ:OVAS) traders have been buying to open calls at a breakneck pace recently. The fertility stock's 10-day call/put volume ratio across the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) is 8.13. In other words, more than eight OVAS calls have been bought to open for every put over the last two weeks.

Elsewhere on the Street, 100% of analysts tracking the security rate it a "strong buy." What's more, OVAS' consensus 12-month price target of $64 represents a 148.6% premium to the current price of $25.74-- as well as never-before-charted waters.

Today's strong price action is vindicating these optimists. At last check, OVAS shares were 4.8% higher, after the company's Augment fertility treatment produced its first-ever birth. Longer term, though, the picture isn't so rosy. OvaScience Inc (NASDAQ:OVAS) has plunged 41.5% year-to-date.

Celebrate 40 Years of Schaeffer's With 4 FREE Stock Picks!


 




 
Special Offers from Schaeffer's Trading Partners